HIV/AIDS HAART: Genotype-guided HAART in early infection may be effective against drug-resistant HIV-1

AIDSWEEKLY Plus; Monday, June 19, 2006
Staff Medical Writers

According to a recently published report in the Journal of Acquired Immune Deficiency Syndromes, "Transmitted resistance to antiretroviral drugs in acute and early HIV-1 infection has been well documented, although overall trends vary depending on geography and cohort characteristics.

"To describe the changing pattern of transmitted drug-resistant HIV-1 in a well-defined cohort in New York City, a total of 361 patients with acute or recent HIV-1 infection were prospectively studied over a decade (1995-2004) with respect to HIV-1 genotypes and longitudinal T-cell subsets and HIV-1 RNA levels."

A. Shet and colleagues at Rockefeller University reported, "The prevalence of overall transmitted resistance changed from 13.2 to 24.1% (p=0.11) during the periods 1995 to 1998 and 2003 to 2004.

"Non-nucleoside reverse transcriptase inhibitor resistance prevalence increased significantly from 2.6 to 13.4% (p=0.007) during the same periods, whereas prevalence of multidrug-resistant virus shifted from 2.6 to 9.8% (p=0.07) but did not achieve statistical significance."

"A compatible immunologic and virologic response of appropriately treated individuals was observed regardless of viral drug susceptibility status, suggesting that initial combination therapy guided by baseline resistance testing in the case of acute and early infection may result in a favorable treatment response even in the case of a drug-resistant virus," researchers said.

The authors concluded, "These data have important implications for selection of empiric first-line regimens for treatment of acutely infected antiretroviral-naive individuals and reinforce the need for baseline resistance testing in acute and early HIV-1 infection."

Shet and colleagues published their study in Journal of Acquired Immune Deficiency Syndromes (Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1 - A decade of experience. J Acquir Immune Defic Syndr. 2006 Apr 1;41(4):439-46).

Additional information can be obtained by contacting M.T. Markowitz, Rockefeller University, Aaron Diamond AIDS Research Center, 455 1st Avenue, 7th Floor, New York City, NY 10016, USA.

The publisher of the Journal of Acquired Immune Deficiency Syndromes can be contacted at: Lippincott Williams & Wilkins, 530 Walnut St., Philadelphia, PA 19106-3621, USA.

Keywords: New York, New York, United States, HIV/AIDS, Genotyping, HAART Initiation, Early Infection, Drug-Resistant Virus.

This article was prepared by AIDS Weekly editors from staff and other reports.

Reference

Shet A, Berry L, Mohri H, Mehandru S, et al., "Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience", J Acquir Immune Defic Syndr. 2006 Apr 1;41(4):439-46.

PubMED Related articles Search

2006-06-19
AW060608

Copyright © 2006 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, Bridgestone/Firestone Charitable Trust, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright © 1980,2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.